Navigation Links
Avaxia Biologics is Awarded U.S. Patent for Antibody Therapy for Modulating Function of Intestinal Receptors and Methods of Treating Diabetes and Obesity
Date:9/18/2012

LEXINGTON, Mass., Sept. 18, 2012 /PRNewswire/ -- Avaxia Biologics, Inc., a privately-held biotechnology company developing oral antibody drugs that act locally within the digestive tract, announced today that the company was awarded U.S. Patent 8,268,971, entitled "Antibody Therapy for Modulating Function of Intestinal Receptors and Methods of Treating Diabetes and Obesity."

The patent covers milk derived antibody compositions that specifically target and modulate an apical intestinal receptor and which are formulated for direct delivery to the gastrointestinal tract of a patient.  The patent also covers treatment of diabetes or obesity by using these antibodies to modulate a sugar receptor.  The types of intestinal receptors disclosed in the patent are very broad, and include sugar transporters, ion channels, sensors, and bile acid transporters.

"This patent highlights the broad applicability of our AVX Oral Antibody technology platform," stated Barbara Fox, PhD, CEO of Avaxia.  "Our oral antibodies can address membrane bound targets as well as soluble targets such as TNF for inflammatory bowel disease and radiation induced damage to the mouth and intestines.  Membrane bound targets such as sugar transporters have been implicated in diabetes and obesity, which are very attractive markets for our oral antibodies."

About Avaxia Biologics:

Avaxia is developing orally administered antibody therapeutics that act locally within the digestive tract.  Antibodies are widely used as therapeutics, with nearly $50 billion in annual sales worldwide.  Ordinary antibodies are injected or infused rather than administered orally because they are destroyed in the digestive tract.  In contrast, we have developed proprietary antibodies that resist digestion.  Our lead product is an oral antibody against tumor necrosis factor (TNF) for inflammatory bowel disease (IBD).  Existing anti-TNF drugs have proven effective for IBD but have serious immunosuppression side effects because they affect the entire body, not just the gastrointestinal (GI) tract where the inflammation occurs.  The goal of our IBD program is to deliver our anti-TNF antibody locally in the GI tract to minimize side effects from systemic drug exposure.  Avaxia also has programs in GI acute radiation syndrome, celiac disease, oral mucositis, diabetes, and obesity.


'/>"/>
SOURCE Avaxia Biologics, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. Avaxia Biologics Announces Appointment of Michael D. Rivard as VP Corporate Development
2. Avaxia Biologics is Awarded U.S. Patent for Method to Treat Radiation Damage to the Digestive Tract and Mucositis Caused by Radiation
3. South and Central America Orthopedic Devices Market Outlook to 2018 - Arthroscopy, Cranio Maxillofacial Fixation (CMF), Hip Reconstruction, Knee Reconstruction, Spinal Surgery, Orthobiologics, Trauma Fixation and Others
4. CMC Biologics Establishes Commercial Presence in Japan through Strategic Agreement with Innomedica
5. Robert G. Savage, Former Worldwide Chairman, Johnson & Johnsons Pharmaceuticals Group, Joins Board of Nuovo Biologics, LLC
6. CMC Biologics Announces Mark W. Sawicki as Vice President, Global Business Development
7. Brazil Orthopedic Devices Market Outlook to 2018 - Arthroscopy, Cranio Maxillofacial Fixation (CMF), Hip Reconstruction, Knee Reconstruction, Spinal Surgery, Orthobiologics, Trauma Fixation and Others
8. WuXi PharmaTech to Manufacture Ibalizumab for TaiMed Biologics
9. Synthetic Biologics Reports Second Quarter 2012 Financial Results
10. Global Spinal Devices and Biologics Market 2011-2015
11. CMC Biologics Acquires XOMAs Bay Area Manufacturing Facility
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/27/2016)... April 27, 2016 Oasmia ... developer of a new generation of drugs within ... survival results for Paclical/Apealea in the Phase III ... with epithelial ovarian cancer. These preliminary results showed ... combination with carboplatin versus Taxol in combination with ...
(Date:4/27/2016)... FRANCISCO , April 27, 2016 ... expected to reach USD 2.06 billion by 2022, ... Research, Inc. Increasing consumer awareness towards a healthy ... the next seven years.      (Logo: ... diet intake coupled with rising health treatment expenditure ...
(Date:4/26/2016)... 26, 2016 Diplomat Pharmacy, Inc. (NYSE: DPLO) ... Hagerman , Pharm D., to Vice President of Education ... Diplomat, Hagerman will continue to lead and oversee Diplomat ... custom education and training to Diplomat employees and external ... Diplomat University also houses the quality assurance department, which ...
Breaking Medicine Technology:
(Date:4/29/2016)... ... April 29, 2016 , ... Our bodies are bombarded daily by ... and deal with these stressors is to adopt a more healthful diet, but too ... Risa Groux, a certified Holistic Nutritionist and the creator of the Newport Beach Cleanse ...
(Date:4/29/2016)... CA (PRWEB) , ... April 29, 2016 , ... ... advocating optimistic healthcare awareness and author of best seller "LOVE, MEDICINE and MIRACLES") ... Radio Monday, May 2, 2016 and podcasted thereafter . Dr. Bernie Siegel, ...
(Date:4/29/2016)... ... 29, 2016 , ... Coast Dental Fort Stewart is celebrating its grand opening ... the Exchange Furniture Mall at 112 Vilseck Road in Fort Stewart. There will be ... attendees will have the opportunity to meet general dentists Thomas Richards, DDS, and Josh ...
(Date:4/29/2016)... ... April 29, 2016 , ... The Wharton ... $30,000 Perlman Grand Prize of the 2016 Wharton Business Plan Competition —as ... People’s Choice Award, and the Committee Award for Most ‘Wow Factor,’ making them ...
(Date:4/29/2016)... ... April 29, 2016 , ... The Gluten-Free Certification ... pleased to announce the launch of the GFCP Scoop in response ... The purpose of the GFCP Scoop site is to keep the ...
Breaking Medicine News(10 mins):